SGI-110. DNA methyltransferase inhibitor, oncolytic

E. A. Griffiths, G. Choy, S. Redkar, P. Taverna, M. Azab, A. R. Karpf

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


SGI-110 is a second-generation hypomethylating prodrug whose active metabolite is the well-characterized drug decitabine. This novel compound is an oligonucleotide consisting of decitabine linked through a phosphodiester bond to the endogenous nucleoside deoxyguanosine. The dinucleotide configuration provides protection from drug clearance by deamination, while maintaining at least equivalent effects on genespecific and global hypomethylation both in vitro and in animal model systems. This agent is currently being tested in phase I and II clinical trials in humans and has been demonstrated to be safe and well tolerated as a single agent, with evidence of promising activity in heavily pretreated (including currently FDA approved hypomethylating drugs) myelodysplastic syndrome and acute myeloid leukemia patients. Ongoing trials are also open in platinum-resistant ovarian cancer and hepatocellular carcinoma.

Original languageEnglish (US)
Pages (from-to)535-543
Number of pages9
JournalDrugs of the Future
Issue number8
StatePublished - Aug 2013


  • Acute myeloid leukemia
  • Hepatocellular carcinoma
  • Hypomethylating prodrug
  • Myelodysplastic syndrome
  • Ovarian cancer
  • SGI-110

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'SGI-110. DNA methyltransferase inhibitor, oncolytic'. Together they form a unique fingerprint.

Cite this